156 related articles for article (PubMed ID: 23675504)
1. Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.
Røe K; Bratland Å; Vlatkovic L; Ragnum HB; Saelen MG; Olsen DR; Marignol L; Ree AH
PLoS One; 2013; 8(5):e63723. PubMed ID: 23675504
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
3. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.
Dagvadorj A; Kirken RA; Leiby B; Karras J; Nevalainen MT
Clin Cancer Res; 2008 Mar; 14(5):1317-24. PubMed ID: 18316550
[TBL] [Abstract][Full Text] [Related]
4. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.
Dagvadorj A; Collins S; Jomain JB; Abdulghani J; Karras J; Zellweger T; Li H; Nurmi M; Alanen K; Mirtti T; Visakorpi T; Bubendorf L; Goffin V; Nevalainen MT
Endocrinology; 2007 Jul; 148(7):3089-101. PubMed ID: 17412813
[TBL] [Abstract][Full Text] [Related]
5. Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.
Røe K; Mikalsen LT; van der Kogel AJ; Bussink J; Lyng H; Ree AH; Marignol L; Olsen DR
Radiat Oncol; 2012 May; 7():75. PubMed ID: 22621752
[TBL] [Abstract][Full Text] [Related]
6. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.
Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
[No Abstract] [Full Text] [Related]
7. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
[TBL] [Abstract][Full Text] [Related]
8. Signal transducer and activator of transcription 5A/B in prostate and breast cancers.
Tan SH; Nevalainen MT
Endocr Relat Cancer; 2008 Jun; 15(2):367-90. PubMed ID: 18508994
[TBL] [Abstract][Full Text] [Related]
9. Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.
Koptyra M; Gupta S; Talati P; Nevalainen MT
Int J Biochem Cell Biol; 2011 Oct; 43(10):1417-21. PubMed ID: 21704724
[TBL] [Abstract][Full Text] [Related]
10. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
Gu L; Zhu XH; Visakorpi T; Alanen K; Mirtti T; Edmonston TB; Nevalainen MT
Anal Cell Pathol (Amst); 2010; 33(2):55-9. PubMed ID: 20966544
[TBL] [Abstract][Full Text] [Related]
11. Metastatic phenotype in CWR22 prostate cancer xenograft following castration.
Seedhouse SJ; Affronti HC; Karasik E; Gillard BM; Azabdaftari G; Smiraglia DJ; Foster BA
Prostate; 2016 Mar; 76(4):359-68. PubMed ID: 26642837
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.
Tan SH; Dagvadorj A; Shen F; Gu L; Liao Z; Abdulghani J; Zhang Y; Gelmann EP; Zellweger T; Culig Z; Visakorpi T; Bubendorf L; Kirken RA; Karras J; Nevalainen MT
Cancer Res; 2008 Jan; 68(1):236-48. PubMed ID: 18172316
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
[TBL] [Abstract][Full Text] [Related]
15. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.
Dagvadorj A; Tan SH; Liao Z; Xie J; Nurmi M; Alanen K; Rui H; Mirtti T; Nevalainen MT
Int J Biochem Cell Biol; 2010 Dec; 42(12):2037-46. PubMed ID: 20854925
[TBL] [Abstract][Full Text] [Related]
16. STAT5A/B gene locus undergoes amplification during human prostate cancer progression.
Haddad BR; Gu L; Mirtti T; Dagvadorj A; Vogiatzi P; Hoang DT; Bajaj R; Leiby B; Ellsworth E; Blackmon S; Ruiz C; Curtis M; Fortina P; Ertel A; Liu C; Rui H; Visakorpi T; Bubendorf L; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Nevalainen MT
Am J Pathol; 2013 Jun; 182(6):2264-75. PubMed ID: 23660011
[TBL] [Abstract][Full Text] [Related]
17. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
18. Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.
Liao Z; Lutz J; Nevalainen MT
Int J Biochem Cell Biol; 2010 Feb; 42(2):186-92. PubMed ID: 19914392
[TBL] [Abstract][Full Text] [Related]
19. Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.
Mirtti T; Leiby BE; Abdulghani J; Aaltonen E; Pavela M; Mamtani A; Alanen K; Egevad L; Granfors T; Josefsson A; Stattin P; Bergh A; Nevalainen MT
Hum Pathol; 2013 Mar; 44(3):310-9. PubMed ID: 23026195
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth.
Gu L; Dagvadorj A; Lutz J; Leiby B; Bonuccelli G; Lisanti MP; Addya S; Fortina P; Dasgupta A; Hyslop T; Bubendorf L; Nevalainen MT
Am J Pathol; 2010 Apr; 176(4):1959-72. PubMed ID: 20167868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
